Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458264 | 0.90 | CYP2C9 (0.47) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL23122103 | 0.90 | ALDH1A1 (0.45) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL1458454 | 0.90 | ALDH1A1 (0.49) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL23122799 | 0.90 | RAB9A (0.47) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL1458539 | 0.89 | KMT2A (0.47) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL16211812 | 0.89 | RAB9A (0.49) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL25332626 | 0.86 | RAB9A (0.44) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL2521960 | 0.84 | KMT2A (0.48) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL8573566 | 0.84 | RAB9A (0.50) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL1406834 | 0.83 | NPC1 (0.49) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4531858-A1 | NOVEL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119300833-A | Novel compounds | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | ORIGIANT PHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| EP-4433480-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| EP-4410787-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | Origiant Pharmaceutical Co., Ltd (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-118234730-A | Heterocyclic NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023232917-A1 | NOVEL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| WO-2014027009-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLE CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-8263584-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2480546-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-8017604-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011036127-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | ALDH1A1 105/4885TSHR 899/4885SMN1; SMN2 1594/4885 |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | PDE10A, PDE4A, PDE3A | ALDH1A1 372/4885TSHR 415/4885SMN1; SMN2 1194/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | ALDH1A1 673/4885TSHR 2162/4885SMN1; SMN2 2265/4885 |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ALDH1A1 2083/4885TSHR 4056/4885SMN1; SMN2 4696/4885 |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | NLRP3, NLRP1, NOD1 | ALDH1A1 1408/4885TSHR 4755/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.